BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Biotech IV Monitor//Trial Readouts//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Biotech trial readouts
X-WR-CALDESC:Upcoming clinical trial readout dates (source: ClinicalTrials.gov)
BEGIN:VEVENT
UID:c568b0f9b76d312cfd34@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280101
SUMMARY:MRUS — Petosemtamab (MCLA-158) (Phase 3)
DESCRIPTION:Merus N.V.. PD-L1+ recurrent/metastatic head and neck squamous cell carcinoma. Expected January 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e7a636391115f139c3db@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280201
SUMMARY:MRUS — Petosemtamab (MCLA-158) (Phase 3)
DESCRIPTION:Merus N.V.. Recurrent/metastatic head and neck squamous cell carcinoma. Expected February 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5a0956682b460deafb89@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:LGND — Lasofoxifene + abemaciclib (Phase 3)
DESCRIPTION:Ligand Pharmaceuticals Incorporated. ER+/HER2- breast cancer with an ESR1 mutation. Expected April 2027 (Enrollment Initiation). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4d6dfc93f1298fdb1ba7@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:ACAD — ACP-211 (Phase 2)
DESCRIPTION:ACADIA Pharmaceuticals Inc.. Major Depressive Disorder (MDD)\; Depressive Disorder\, Treatment-Resistant. Expected August 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ead718bf0ad169de3578@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280101
SUMMARY:ACAD — ACP-204 (Phase 2/3)
DESCRIPTION:ACADIA Pharmaceuticals Inc.. Alzheimer's Disease Psychosis. Expected January 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2479f035fd0968f93341@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280201
SUMMARY:ACAD — ACP-204 (Phase 2)
DESCRIPTION:ACADIA Pharmaceuticals Inc.. Lewy Body Dementia Psychosis. Expected February 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7c66d2fa15a8eeefc7cb@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290201
SUMMARY:ACAD — ACP-204 (Phase 3)
DESCRIPTION:ACADIA Pharmaceuticals Inc.. Lewy Body Dementia Psychosis. Expected February 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:29cadcfb4b2a4f0d7ea5@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290401
SUMMARY:ACAD — ACP-204 (Phase 3)
DESCRIPTION:ACADIA Pharmaceuticals Inc.. Alzheimer's Disease Psychosis. Expected April 2029 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1fc655579b30ced0de9f@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290301
SUMMARY:AGIO — Mitapivat (Phase 3)
DESCRIPTION:Agios Pharmaceuticals Inc.. Non-Transfusion-dependent Alpha-Thalassemia\; Non-Transfusion-dependent Beta-Thalassemia. Expected March 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:28c02f207d328e457874@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290601
SUMMARY:AGIO — Mitapivat Matched Placebo (Phase 3)
DESCRIPTION:Agios Pharmaceuticals Inc.. Transfusion-dependent Alpha-Thalassemia\; Transfusion-dependent Beta-Thalassemia. Expected June 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e32cf9c6fc338fda9dc6@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290801
SUMMARY:AGIO — Mitapivat Matched Placebo (Phase 3)
DESCRIPTION:Agios Pharmaceuticals Inc.. Sickle Cell Disease. Expected August 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:dd04a4f7ca1c08ec8308@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300801
SUMMARY:AGIO — AG-236 (Phase 2/3)
DESCRIPTION:Agios Pharmaceuticals Inc.. Polycythemia Vera. Expected August 2030 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c45569cb62a6e3fc778e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:ALMS — envudeucitinib (Phase 2)
DESCRIPTION:Alumis Inc.. Plaque Psoriasis. Expected December 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3bc23ebbf389770db190@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281101
SUMMARY:ALMS — Open-Label Envudeucitinib (Phase 3)
DESCRIPTION:Alumis Inc.. Plaque Psoriasis\; Psoriasis (PsO). Expected November 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:911553f692bd8f45697d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280401
SUMMARY:ARQT — Roflumilast Cream 0.3% (Phase 3)
DESCRIPTION:Arcutis Biotherapeutics Inc.. Atopic Dermatitis\; Atopic Dermatitis (AD). Expected April 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ba98de39b48ea121aab7@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:BHVN — BHV-7000 (Phase 2)
DESCRIPTION:Biohaven Ltd.. Focal Epilepsy. Expected December 2026 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ba98de39b48ea121aab7@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:BHVN — BHV-7000 (Phase 2/3)
DESCRIPTION:Biohaven Ltd.. Focal Epilepsy. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0e949e13ff960f9899ec@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:BHVN — BHV-8000 10mg (Phase 2/3)
DESCRIPTION:Biohaven Ltd.. Parkinson Disease. Expected August 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3773ee3f77de5a913ca7@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280101
SUMMARY:BHVN — BHV-1300 (Phase 3)
DESCRIPTION:Biohaven Ltd.. Graves Disease. Expected January 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:43b3890f7f93aa71b594@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280201
SUMMARY:BHVN — BHV-1510 (Phase 1/2)
DESCRIPTION:Biohaven Ltd.. Solid Tumor. Expected February 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:04a4c1f0c2edb5c80375@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280901
SUMMARY:BHVN — BHV-1400 (Phase 3)
DESCRIPTION:Biohaven Ltd.. IgA Nephropathy. Expected September 2028 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5ead97a561a7d65ffcef@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281201
SUMMARY:BHVN — BHV-1300 (Phase 2/3)
DESCRIPTION:Biohaven Ltd.. Graves' Disease. Expected December 2028 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3fcc2752de9d6033b497@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:BLTE — Tinlarebant (Phase 3)
DESCRIPTION:Belite Bio Inc. Geographic Atrophy. Expected June 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3fa1ed1e6d95b4bedae1@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280201
SUMMARY:BLTE — Tinlarebant (Phase 2/3)
DESCRIPTION:Belite Bio Inc. STGD1\; Stargardt Disease 1. Expected February 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ea70e87c95f3a7f1f6f6@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:BPMC — BLU-808 (Phase 2)
DESCRIPTION:Blueprint Medicines Corporation. Chronic Inducible Urticaria\; Chronic Spontaneous Urticaria. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:177088f34bce8ae4222f@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:BPMC — Avapritinib (Phase 2)
DESCRIPTION:Blueprint Medicines Corporation. Indolent Systemic Mastocytosis. Expected June 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:636da18fea77643788aa@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290901
SUMMARY:BPMC — BLU-924 (Phase 1/2)
DESCRIPTION:Blueprint Medicines Corporation. Advanced Solid Tumor\; Non-Small Cell Lung Cancer. Expected September 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c5b19dcc92446b1c465d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20320901
SUMMARY:BPMC — Elenestinib (Phase 2/3)
DESCRIPTION:Blueprint Medicines Corporation. Indolent Systemic Mastocytosis\; Smoldering Systemic Mastocytosis. Expected September 2032 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9051c1b602abb1dab79f@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280101
SUMMARY:CELC — Gedatolisib (Phase 1/2)
DESCRIPTION:Celcuity Inc.. mCRPC (Metastatic Castration-resistant Prostate Cancer)\; Genital Diseases\, Male. Expected January 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:46eae97268688e1539e3@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290301
SUMMARY:CELC — Arm A: Gedatolisib + Palbociclib + Fulvestrant (Phase 3)
DESCRIPTION:Celcuity Inc.. Breast Cancer. Expected March 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6cdcc3579ca986d59f46@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:CGON — Cretostimogene Grenadenorepvec (Phase 2)
DESCRIPTION:CG Oncology\, Inc.. High-Risk Non-Muscle-Invasive Bladder Cancer. Expected March 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:db342555cd81bbd3e02c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300601
SUMMARY:CGON — Cretostimogene Grenadenorepvec (Phase 3)
DESCRIPTION:CG Oncology\, Inc.. Non Muscle Invasive Bladder Cancer\; High-grade Ta/ T1 Papillary Disease Bladder Cancer. Expected June 2030 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0d189d15536346750946@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280601
SUMMARY:CLDX — Barzolvolimab (Phase 3)
DESCRIPTION:Celldex Therapeutics Inc.. Chronic Inducible Urticaria\; Cold Urticaria. Expected June 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8a53800b14cdaef54eb1@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280901
SUMMARY:CLDX — barzolvolimab (Phase 3)
DESCRIPTION:Celldex Therapeutics Inc.. Chronic Spontaneous Urticaria. Expected September 2028 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c4f885d01ed084af65eb@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:CNTA — ORX750 (Phase 2)
DESCRIPTION:Centessa Pharmaceuticals plc. Narcolepsy Type 1\; Narcolepsy Type 2. Expected December 2026 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:acc3faf74f6db40c07e6@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270901
SUMMARY:CNTA — cleminorexton (Phase 2/3)
DESCRIPTION:Centessa Pharmaceuticals plc. Narcolepsy Type 1\; Narcolepsy Type 2. Expected September 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:594be2ccf14e81bfcf84@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270701
SUMMARY:COAG — HMB-002 (Part A) (Phase 1/2)
DESCRIPTION:Hemab Therapeutics Holdings Inc.. Von Willebrand Disease (VWD)\; Von Willebrand Disease (VWD)\, Type 1. Expected July 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ec3df32a9e84cccbb2b1@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:COAG — HMB-001 (Phase 1/2)
DESCRIPTION:Hemab Therapeutics Holdings Inc.. Glanzmann Thrombasthenia. Expected August 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:523a21fa18ca736250e6@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271101
SUMMARY:COAG — Sutacimig (Phase 2)
DESCRIPTION:Hemab Therapeutics Holdings Inc.. Congenital Factor VII Deficiency. Expected November 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4f0e5db47813b3c8b65f@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20291101
SUMMARY:COAG — Sutacimig (Phase 3)
DESCRIPTION:Hemab Therapeutics Holdings Inc.. Thrombasthenia. Expected November 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:07d510258443b40fb3df@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:CRNX — Atumelnant (Phase 3)
DESCRIPTION:Crinetics Pharmaceuticals Inc.. Congenital Adrenal Hyperplasia\; Classic Congenital Adrenal Hyperplasia. Expected May 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1e2b2cfff84e523df274@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:CRNX — Paltusotine (Phase 3)
DESCRIPTION:Crinetics Pharmaceuticals Inc.. Carcinoid Syndrome\; Carcinoid. Expected August 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3c8194f1d4f509a5035c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:CRNX — CRN09682 (Phase 1/2)
DESCRIPTION:Crinetics Pharmaceuticals Inc.. SST2-positive Neuroendocrine Neoplasms\; Neuroendocrine Tumors. Expected August 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a5318fe15289988c00d1@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290701
SUMMARY:CRNX — atumelnant (CRN04894) (Phase 2)
DESCRIPTION:Crinetics Pharmaceuticals Inc.. Congenital Adrenal Hyperplasia\; Classic Congenital Adrenal Hyperplasia. Expected July 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2ac52f031c11371ebc29@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300301
SUMMARY:CRNX — Atumelnant (Phase 2/3)
DESCRIPTION:Crinetics Pharmaceuticals Inc.. Congenital Adrenal Hyperplasia\; Classic Congenital Adrenal Hyperplasia. Expected March 2030 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2bf63367c63a4e3eee75@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280701
SUMMARY:CRSP — CTX340 (Phase 1/2)
DESCRIPTION:CRISPR Therapeutics AG. Hypertension. Expected July 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d1698a2a0bc18657d416@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20291201
SUMMARY:CRSP — CTX112 (Phase 1/2)
DESCRIPTION:CRISPR Therapeutics AG. Progressive Multiple Sclerosis (PMS)\; Neuromyelitis Optica. Expected December 2029 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:598f8833ac0cda8ba5e0@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300101
SUMMARY:CRSP — CTX112 (Phase 1/2)
DESCRIPTION:CRISPR Therapeutics AG. B-cell Lymphoma\; Non-Hodgkin Lymphoma. Expected January 2030 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d1c198129c05ea962230@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300601
SUMMARY:CRSP — CTX460 (Phase 1/2)
DESCRIPTION:CRISPR Therapeutics AG. Alpha-1 Antitrypsin Deficiency (AATD). Expected June 2030 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e63bb1dcadeaae1b1fef@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20331201
SUMMARY:CRSP — CTX112 (Phase 1/2)
DESCRIPTION:CRISPR Therapeutics AG. Warm Autoimmune Hemolytic Anemia (WAIHA)\; ITP - Immune Thrombocytopenia. Expected December 2033 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6b7e64abad92e521597e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:DCPH — Inlexisertib (Phase 1/2)
DESCRIPTION:Deciphera Pharmaceuticals Inc.. GIST. Expected March 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e66b0fa1f478025da5e2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:DCPH — Ripretinib (Phase 3)
DESCRIPTION:Deciphera Pharmaceuticals Inc.. GIST. Expected December 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:bc747d5d2e8cf9557dfa@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280501
SUMMARY:DCPH — DCC-3009 (Phase 1/2)
DESCRIPTION:Deciphera Pharmaceuticals Inc.. Gastrointestinal Stromal Tumor (GIST). Expected May 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:cc01940d3b69c12ef7b8@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280801
SUMMARY:DCPH — Vimseltinib (Phase 1/2)
DESCRIPTION:Deciphera Pharmaceuticals Inc.. Advanced Malignant Neoplasm\; Pigmented Villonodular Synovitis. Expected August 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7928caae4585d75a63fc@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20291001
SUMMARY:DCPH — Vimseltinib (Phase 2)
DESCRIPTION:Deciphera Pharmaceuticals Inc.. Chronic Graft-Versus-Host Disease (cGVHD). Expected October 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:955b284a56dc382ae251@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270901
SUMMARY:DFTX — DT120 (Phase 3)
DESCRIPTION:Definium Therapeutics Inc.. Major Depressive Disorder. Expected September 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:fa49717897e29368f612@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:DNLI — DNL593 (Phase 1/2)
DESCRIPTION:Denali Therapeutics Inc.. Frontotemporal Dementia. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7ea0361aa352af085d74@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:DNLI — BIIB122 225 mg (Phase 2)
DESCRIPTION:Denali Therapeutics Inc.. Parkinson Disease. Expected March 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9554da6b1bd6875517be@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:DNLI — tividenofusp alfa (Phase 2/3)
DESCRIPTION:Denali Therapeutics Inc.. Mucopolysaccharidosis II. Expected June 2027 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f696efbd92080982e916@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:DNLI — tividenofusp alfa (Phase 2/3)
DESCRIPTION:Denali Therapeutics Inc.. Mucopolysaccharidosis II. Expected December 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0077a9c46032d5c18ef2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20310201
SUMMARY:DNLI — tividenofusp alfa (Phase 1/2)
DESCRIPTION:Denali Therapeutics Inc.. Mucopolysaccharidosis II. Expected February 2031 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:cff27476175995d0c665@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20320701
SUMMARY:DNLI — DNL126 (Phase 1/2)
DESCRIPTION:Denali Therapeutics Inc.. Mucopolysaccharidosis Type IIIA. Expected July 2032 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:51dc9bd8485781f3743c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:DNTH — Claseprubart (Phase 2)
DESCRIPTION:Dianthus Therapeutics Inc.. Multifocal Motor Neuropathy. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:56ab1c29a8ffb15db8d2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281201
SUMMARY:DNTH — Claseprubart (Phase 3)
DESCRIPTION:Dianthus Therapeutics Inc.. Myasthenia Gravis\, Generalized. Expected December 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:56ab1c29a8ffb15db8d2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281201
SUMMARY:DNTH — Claseprubart (Phase 3)
DESCRIPTION:Dianthus Therapeutics Inc.. Chronic Inflammatory Demyelinating Polyneuropathy. Expected December 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c6752f4036399a6e2135@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280701
SUMMARY:DYN — zeleciment basivarsen (DYNE-101) (Phase 3)
DESCRIPTION:Dyne Therapeutics Inc.. Myotonic Dystrophy Type 1 (DM1)\; DM1. Expected July 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c653b796cb681f6ef450@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290701
SUMMARY:DYN — DYNE-101 (Phase 1/2)
DESCRIPTION:Dyne Therapeutics Inc.. Myotonic Dystrophy Type 1 (DM1). Expected July 2029 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:683199569b6684252642@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20301201
SUMMARY:DYN — Zeleciment Rostudirsen (DYNE-251) (Phase 3)
DESCRIPTION:Dyne Therapeutics Inc.. Duchenne Muscular Dystrophy (DMD)\; Muscular Dystrophy\, Duchenne. Expected December 2030 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7c2dd85c648a72068abe@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20310901
SUMMARY:DYN — DYNE-251 (Phase 1/2)
DESCRIPTION:Dyne Therapeutics Inc.. Duchenne Muscular Dystrophy (DMD). Expected September 2031 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:49f9aadf9ae6a2eb3a40@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281201
SUMMARY:ELVN — ELVN-001 (Phase 3)
DESCRIPTION:Enliven Therapeutics Inc.. Chronic Myeloid Leukemia (CML)\; Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive. Expected December 2028 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:52387f04e12c178761e9@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280401
SUMMARY:ERAS — Naporafenib (Phase 3)
DESCRIPTION:Erasca Inc.. Advanced or Metastatic NRAS-mutant Melanoma. Expected April 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:36a8af62e5cd0a734102@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:EWTX — Sevasemten Dose 1 (Phase 2)
DESCRIPTION:Edgewise Therapeutics Inc.. Duchenne Muscular Dystrophy. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c1293fe01de4f2f98983@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:EWTX — Sevasemten Dose 1 (Phase 2)
DESCRIPTION:Edgewise Therapeutics Inc.. Duchenne Muscular Dystrophy. Expected March 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0a4f00ef6407d5c98dc8@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:EWTX — EDG-15400 25 mg (Phase 2)
DESCRIPTION:Edgewise Therapeutics Inc.. Heart Failure With Preserved Ejection Fraction. Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8eb81ab1afee10334e0f@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:EWTX — EDG-7500 (Phase 2)
DESCRIPTION:Edgewise Therapeutics Inc.. Hypertrophic Cardiomyopathy. Expected December 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f22eb9b8c5775fadb140@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20310201
SUMMARY:EWTX — Sevasemten (Phase 2)
DESCRIPTION:Edgewise Therapeutics Inc.. Becker Muscular Dystrophy. Expected February 2031 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:228447d38775d7ea55cd@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:GKOS — GLK-221 Ophthalmic Solution (Phase 2)
DESCRIPTION:Glaukos Corporation. Keratoconus. Expected April 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c28352e2bf1e8069f94b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280301
SUMMARY:GKOS — Gen 2 Travoprost Intracameral Implant (Phase 2)
DESCRIPTION:Glaukos Corporation. Glaucoma. Expected March 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:73b495370b58a449a581@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280601
SUMMARY:GKOS — Gen 2 Travoprost Intracameral Implant (Phase 3)
DESCRIPTION:Glaukos Corporation. Glaucoma. Expected June 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ef150f7e895be7f685af@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270901
SUMMARY:GRFS — Alpha-1 15% (Phase 3)
DESCRIPTION:Grifols S.A.. Alpha 1 Antitrypsin Deficiency. Expected September 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:165c752213ffc262f789@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:GRFS — Gamunex-C (Phase 3)
DESCRIPTION:Grifols S.A.. CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy). Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b1b8a4d96dbb6128de6c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280801
SUMMARY:GRFS — Gamunex-C\, 10% Injectable Solution (Phase 3)
DESCRIPTION:Grifols S.A.. Chronic Lymphocytic Leukemia\, Multiple Myeloma\, or Non-Hodgkin Lymphoma. Expected August 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4a2e00c1cd9816769e7c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280901
SUMMARY:GRFS — Alpha-1 MP (Phase 3)
DESCRIPTION:Grifols S.A.. Pulmonary Emphysema in Alpha-1 Antitrypsin Deficiency. Expected September 2028 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:dff20b86cfcbf27aa306@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290801
SUMMARY:GRFS — Xembify (Phase 3)
DESCRIPTION:Grifols S.A.. Hypogammaglobulinemia\; Bacterial Infections. Expected August 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:945ada424571a61c6877@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280301
SUMMARY:HALO — Testosterone enanthate (Phase 3)
DESCRIPTION:Halozyme Therapeutics Inc.. Hypogonadism\, Male. Expected March 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:87b5fc2b923b57321fa8@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:HRMY — Pitolisant tablet (Phase 3)
DESCRIPTION:Harmony Biosciences Holdings Inc.. Prader-Willi Syndrome. Expected April 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8195a0ed30400974958b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271001
SUMMARY:HRMY — HBS-301 tablet (Phase 3)
DESCRIPTION:Harmony Biosciences Holdings Inc.. Idiopathic Hypersomnia. Expected October 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:681cdb689d63952c5515@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271001
SUMMARY:HRMY — HBS-301 (Phase 3)
DESCRIPTION:Harmony Biosciences Holdings Inc.. EDS\; Cataplexy. Expected October 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4ed6bd76c530dd2377ba@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300801
SUMMARY:HRMY — Pitolisant (Phase 3)
DESCRIPTION:Harmony Biosciences Holdings Inc.. Prader-Willi Syndrome. Expected August 2030 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e31cb30e0b118849556c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:IBRX — Anktiva (Phase 2)
DESCRIPTION:ImmunityBio Inc.. Long COVID\; Long COVID Syndrome. Expected March 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1b57b866f072f49fc185@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:IBRX — Gemcitabine (Phase 2)
DESCRIPTION:ImmunityBio Inc.. Platinum-resistant Ovarian Cancer. Expected May 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:05071ed6201dc268ceb3@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:IBRX — CD19 t-haNK- IV Administration (Phase 2)
DESCRIPTION:ImmunityBio Inc.. Relapsed B-Cell Non Hodgkin Lymphoma. Expected May 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:be7f13711b0d4da94ae0@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:IBRX — Nogapendekin alfa inbakicept (NAI) (Phase 2)
DESCRIPTION:ImmunityBio Inc.. Sepsis\; Septic Shock. Expected August 2027 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9659fe441afea6feaa25@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:IBRX — CD19 t-haNK- IV Administration (Phase 2)
DESCRIPTION:ImmunityBio Inc.. Relapsed B-Cell Non-Hodgkin Lymphoma. Expected December 2027 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8aca554e005dc7de41d7@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280201
SUMMARY:IBRX — Intravesical Recombinant Mycobacterium (rMBCG) (Phase 1/2)
DESCRIPTION:ImmunityBio Inc.. NMIBC. Expected February 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:413599df4a2a884ceb9c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280501
SUMMARY:IBRX — Nogapendekin alfa inbakicept (NAI) (Phase 2)
DESCRIPTION:ImmunityBio Inc.. Sepsis. Expected May 2028 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:adf171ad540b344e7bf2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280901
SUMMARY:IBRX — N-803 (Phase 3)
DESCRIPTION:ImmunityBio Inc.. NSCLC Stage IV. Expected September 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c20e5abc86a2bb6b5b49@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290801
SUMMARY:IBRX — N-803 + Pembrolizumab (Phase 2)
DESCRIPTION:ImmunityBio Inc.. Non-Small Cell Lung Cancer\; Small Cell Lung Cancer. Expected August 2029 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ef6efc80dd13eae2b7c6@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:IDYA — IDE196 (Phase 2/3)
DESCRIPTION:IDEAYA Biosciences Inc.. Metastatic Uveal Melanoma. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ef6efc80dd13eae2b7c6@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:IDYA — IDE196 (Phase 1/2)
DESCRIPTION:IDEAYA Biosciences Inc.. Metastatic Uveal Melanoma\; Cutaneous Melanoma. Expected January 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b389f760231da6fc4db0@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:IDYA — Darovasertib (Phase 2)
DESCRIPTION:IDEAYA Biosciences Inc.. Uveal Melanoma. Expected April 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b50f827f94e1bb3bf867@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290701
SUMMARY:IDYA — IDE849 (Phase 1/2)
DESCRIPTION:IDEAYA Biosciences Inc.. Small-cell Lung Cancer\; Neuroendocrine Carcinomas. Expected July 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1e07ab4a5f4fa79c0249@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20301001
SUMMARY:IDYA — Darovasertib (Phase 3)
DESCRIPTION:IDEAYA Biosciences Inc.. Uveal Melanoma. Expected October 2030 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1a84b92bf9d436ad22c8@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20340301
SUMMARY:IDYA — Darovasertib (Phase 3)
DESCRIPTION:IDEAYA Biosciences Inc.. Uveal Melanoma. Expected March 2034 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2aa5a574345642386bfb@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:IMVT — IMVT-1402 (Phase 2)
DESCRIPTION:Immunovant Inc.. Graves' Disease. Expected May 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c4a9b88bc6aa7769f554@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270901
SUMMARY:IMVT — IMVT-1402 (Phase 2)
DESCRIPTION:Immunovant Inc.. Rheumatoid Arthritis. Expected September 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7042b1cc0fcfdba83cf1@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:IMVT — IMVT-1402 (Phase 3)
DESCRIPTION:Immunovant Inc.. Generalized Myasthenia Gravis. Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:663501a68f4c8092aadb@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280601
SUMMARY:IMVT — IMVT-1402 (Phase 2)
DESCRIPTION:Immunovant Inc.. Graves' Disease. Expected June 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e0b4ceb731a7007f5486@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280701
SUMMARY:IMVT — IMVT-1402 (Phase 2)
DESCRIPTION:Immunovant Inc.. Primary Sjögren's Syndrome. Expected July 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:bf6a233d9ebd0dea999f@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280801
SUMMARY:IMVT — Imeroprubart (Phase 2)
DESCRIPTION:Immunovant Inc.. Chronic Inflammatory Demyelinating Polyneuropathy. Expected August 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:834bb30bc8531481e9d7@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300301
SUMMARY:IMVT — IMVT-1402 (Phase 2)
DESCRIPTION:Immunovant Inc.. Graves' Disease. Expected March 2030 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:71451cf9555a132becc9@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:IONS — Donidalorsen (Phase 3)
DESCRIPTION:Ionis Pharmaceuticals Inc.. Hereditary Angioedema. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:053e62d3403cfe82fc44@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:IONS — Olezarsen (Phase 3)
DESCRIPTION:Ionis Pharmaceuticals Inc.. Severe Hypertriglyceridemia. Expected March 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:27c2f82287e0ef32f0b4@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:IONS — ION717 (Phase 1/2)
DESCRIPTION:Ionis Pharmaceuticals Inc.. Prion Disease. Expected April 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3aaf3ad0a74f066ef76b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:IONS — Olezarsen (Phase 3)
DESCRIPTION:Ionis Pharmaceuticals Inc.. Familial Chylomicronemia Syndrome. Expected June 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ebac3a1355172c7dfdb4@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:IONS — obudanersen (Phase 3)
DESCRIPTION:Ionis Pharmaceuticals Inc.. Angelman Syndrome. Expected August 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:282bb4d69bc000ea6a04@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270901
SUMMARY:IONS — ION775 (Phase 2)
DESCRIPTION:Ionis Pharmaceuticals Inc.. Hypertriglyceridemia\; Severe Hypertriglyceridemia. Expected September 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d780e951cb2324451e31@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270901
SUMMARY:IONS — ION440 (Phase 1/2)
DESCRIPTION:Ionis Pharmaceuticals Inc.. Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome. Expected September 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a50270c53f83f32c05f5@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280201
SUMMARY:IONS — Olezarsen (Phase 3)
DESCRIPTION:Ionis Pharmaceuticals Inc.. Familial Chylomicronemia Syndrome. Expected February 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4e1e2a1deb5e18996c5d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280501
SUMMARY:IONS — obudanersen (Phase 3)
DESCRIPTION:Ionis Pharmaceuticals Inc.. Angelman Syndrome. Expected May 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5a26b47989dd7e4e385e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290301
SUMMARY:IONS — ION582 (Phase 1/2)
DESCRIPTION:Ionis Pharmaceuticals Inc.. Angelman Syndrome. Expected March 2029 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:31ee6d27c7e25258756c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:IRON — DISC-0974 (Phase 1/2)
DESCRIPTION:Disc Medicine Inc.. Myelofibrosis\; Anemia\; Anemia. Expected May 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:dee7855d6d191ead33d0@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270701
SUMMARY:IRON — DISC-3405 (Phase 2)
DESCRIPTION:Disc Medicine Inc.. Polycythemia Vera (PV). Expected July 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4c512ca8c068caee5c4c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280601
SUMMARY:IRON — DISC-1459 (Phase 2/3)
DESCRIPTION:Disc Medicine Inc.. Erythropoietic Protoporphyria. Expected June 2028 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2591b29c89f698491da6@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:KLRA — Ribupatide (Phase 2)
DESCRIPTION:Kailera Therapeutics Inc.. Obesity. Expected May 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d62a7c19ad6b41abe7bf@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270701
SUMMARY:KLRA — KAI-7535 (Phase 2)
DESCRIPTION:Kailera Therapeutics Inc.. Obesity\; Overweight. Expected July 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:05ad5a51210e6a303281@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280201
SUMMARY:KLRA — Ribupatide (Phase 3)
DESCRIPTION:Kailera Therapeutics Inc.. Obesity\; Overweight. Expected February 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7ce2e542ecb3b751bb0c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280301
SUMMARY:KLRA — Ribupatide (Phase 3)
DESCRIPTION:Kailera Therapeutics Inc.. Obesity. Expected March 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7ce2e542ecb3b751bb0c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280301
SUMMARY:KLRA — Ribupatide (Phase 3)
DESCRIPTION:Kailera Therapeutics Inc.. Obesity With Diabetes\; Overweight With Diabetes. Expected March 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1e9d9cda743188ab36d2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:KNSA — KPL-387 (Phase 2/3)
DESCRIPTION:Kiniksa Pharmaceuticals International plc. Pericarditis\; Pericarditis Acute. Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1e9d9cda743188ab36d2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:KNSA — KPL-387 (Phase 2)
DESCRIPTION:Kiniksa Pharmaceuticals International plc. Recurrent Pericarditis\; Heart Diseases. Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:80d0cb15a41c85a79a80@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270201
SUMMARY:KOD — KSI-101 (Phase 3)
DESCRIPTION:Kodiak Sciences Inc. Macular Edema Secondary to Inflammation. Expected February 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5c1c3bfcd6aef3a0d003@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:KOD — KSI-101 (Phase 3)
DESCRIPTION:Kodiak Sciences Inc. Macular Edema Secondary to Inflammation. Expected April 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4036f1d25f6f39bb1d1e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280801
SUMMARY:KOD — Tabirafusp tedromer (Phase 3)
DESCRIPTION:Kodiak Sciences Inc. Diabetic Macular Edema (DME). Expected August 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4265699efbc6fc107838@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:KRYS — KB803 (Phase 3)
DESCRIPTION:Krystal Biotech Inc.. Dystrophic Epidermolysis Bullosa\; DEB - Dystrophic Epidermolysis Bullosa. Expected December 2026 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c41eee7dafceca19c481@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:KRYS — KB801 (Phase 1/2)
DESCRIPTION:Krystal Biotech Inc.. Neurotrophic Keratitis. Expected December 2026 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:bc99ccef1e3d222f139d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270201
SUMMARY:KRYS — KB707 (Phase 1/2)
DESCRIPTION:Krystal Biotech Inc.. Lung Cancer\, Non-small Cell\; Lung Cancer Metastatic. Expected February 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:da5a52c5205471fbf74e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270701
SUMMARY:KRYS — KB707 (Phase 1/2)
DESCRIPTION:Krystal Biotech Inc.. Cancer\; Melanoma Stage III. Expected July 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e6ec489a9d0943769d79@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:KYKOF — ziftomenib (Phase 2)
DESCRIPTION:Kyowa Kirin Co. Ltd.. Acute Myeloid Leukemia (AML). Expected March 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e3124adf16c07c812dd1@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:KYKOF — KK2430 (Phase 1/2)
DESCRIPTION:Kyowa Kirin Co. Ltd.. Hematologic Neoplasms. Expected April 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7a95d74c3ce086682043@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280501
SUMMARY:KYKOF — ME-401 (Phase 2)
DESCRIPTION:Kyowa Kirin Co. Ltd.. Indolent B-cell Non-Hodgkin's Lymphoma. Expected May 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6dfe10d955c6eb2ff7ac@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290501
SUMMARY:KYKOF — KK8398 (Phase 3)
DESCRIPTION:Kyowa Kirin Co. Ltd.. Achondroplasia. Expected May 2029 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ef914f1fa67a7447deb5@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300601
SUMMARY:KYKOF — KK8123 (Phase 1/2)
DESCRIPTION:Kyowa Kirin Co. Ltd.. X-linked Hypophosphatemia. Expected June 2030 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:668ee3b93b83885ccc75@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:KYMR — KT-621 (Phase 2)
DESCRIPTION:Kymera Therapeutics Inc.. Atopic Dermatitis. Expected June 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:dd6119b40d0936490ef3@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:KYMR — KT-621 (Phase 2)
DESCRIPTION:Kymera Therapeutics Inc.. Eosinophilic Asthma. Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:80887bbce01b43d2834c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281201
SUMMARY:KYMR — KT-621 (Phase 2)
DESCRIPTION:Kymera Therapeutics Inc.. Asthma (Diagnosis). Expected December 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6fc93fd4ab86aad973b4@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:LBPH — LP352 (Phase 3)
DESCRIPTION:Longboard Pharmaceuticals Inc.. Dravet Syndrome. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5a359d65bdb2e79ea812@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271101
SUMMARY:LBPH — LP352 (Phase 3)
DESCRIPTION:Longboard Pharmaceuticals Inc.. Developmental and Epileptic Encephalopathy. Expected November 2027 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ac1b29598a24cd628148@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:LNTH — LNTH2403 Phase 1 dose (Phase 1/2)
DESCRIPTION:Lantheus Holdings Inc.. Relapsed / Refractory Osteosarcoma. Expected August 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d80af9ebf543a800ca0c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280301
SUMMARY:LNTH — [18F]PI-2620 (Phase 3)
DESCRIPTION:Lantheus Holdings Inc.. Alzheimer Disease. Expected March 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9ecaa02760d1d051bb78@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290901
SUMMARY:LNTH — [68Ga]-LNTH-2401 (Phase 2/3)
DESCRIPTION:Lantheus Holdings Inc.. Prostate Cancer. Expected September 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:08794023abd3b6751597@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270201
SUMMARY:LQDA — LIQ861 (treprostinil) inhalation powder (Phase 2)
DESCRIPTION:Liquidia Corporation. Raynaud's Phenomenon Secondary to Systemic Sclerosis. Expected February 2027 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:70e43772e80d19eb584a@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290701
SUMMARY:LQDA — L606 (Phase 3)
DESCRIPTION:Liquidia Corporation. Pulmonary Hypertension Due to Lung Disease (Disorder). Expected July 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9fba4b0dac381f3bb5ae@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:MANE — VDPHL01 (Phase 3)
DESCRIPTION:Veradermics Incorporated. Androgenetic Alopecia\; AGA. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e694e3ae5571d65e60b6@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:MANE — VDPHL01 QD (Phase 3)
DESCRIPTION:Veradermics Incorporated. Androgenetic Alopecia (AGA)\; Androgenetic Alopecia. Expected June 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:aa7b9d2b89d8bba0e761@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280101
SUMMARY:MBX — Canvuparatide (Phase 3)
DESCRIPTION:MBX Biosciences Inc.. Hypoparathyroidism. Expected January 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8772431eebf4c5e7da4e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280501
SUMMARY:MBX — 400 µg of MBX 2109 once-weekly by subcutaneous injection (Phase 2)
DESCRIPTION:MBX Biosciences Inc.. Hypoparathyroidism. Expected May 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f97a11023e934526e377@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:MIRM — Volixibat (Phase 2)
DESCRIPTION:Mirum Pharmaceuticals Inc.. Primary Biliary Cholangitis\; PBC. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1e6c5f5c4a9b78d113b2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:MIRM — Brelovitug 300 mg (Phase 3)
DESCRIPTION:Mirum Pharmaceuticals Inc.. Chronic Hepatitis D Infection. Expected June 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a0e016b5a707eced1af3@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:MIRM — Brelovitug (BJT-778) (Phase 2/3)
DESCRIPTION:Mirum Pharmaceuticals Inc.. Chronic Hepatitis D. Expected August 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b7bacd6819a645a25238@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271001
SUMMARY:MIRM — Low dose of MRM-3379 (Phase 2)
DESCRIPTION:Mirum Pharmaceuticals Inc.. Fragile X Syndrome. Expected October 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:293946f0459bdcdb5897@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290101
SUMMARY:MIRM — Maralixibat (Phase 2)
DESCRIPTION:Mirum Pharmaceuticals Inc.. Intrahepatic Cholestasis of Pregnancy. Expected January 2029 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:21718201abf690745f27@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290501
SUMMARY:MIRM — Brelovitug 300 mg (Phase 2/3)
DESCRIPTION:Mirum Pharmaceuticals Inc.. Chronic Hepatitis D Infection. Expected May 2029 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b9fde720965a9d6d592b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271101
SUMMARY:NAMS — obicetrapib 10 mg + ezetimibe 10 mg FDC daily (Phase 3)
DESCRIPTION:NewAmsterdam Pharma Company N.V.. Lipidemia\; Coronary Artery Disease. Expected November 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e79ce9f25556f064aa9a@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280301
SUMMARY:NAMS — obicetrapib 10 mg + ezetimibe 10 mg FDC daily (Phase 3)
DESCRIPTION:NewAmsterdam Pharma Company N.V.. Lipidemia\; Type 2 Diabetes (T2DM). Expected March 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:974fe7d6611c9c634fee@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280901
SUMMARY:NAMS — Obicetrapib 10 mg (Phase 2)
DESCRIPTION:NewAmsterdam Pharma Company N.V.. Preclinical Alzheimer's Disease. Expected September 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:757baaa1f1992f7e7f29@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280501
SUMMARY:NKTR — Rezpegaldesleukin (Phase 3)
DESCRIPTION:Nektar Therapeutics. Moderate-to-Severe Atopic Dermatitis. Expected May 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3ed01e5446926a272872@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280601
SUMMARY:NKTR — Rezpegaldesleukin (Phase 3)
DESCRIPTION:Nektar Therapeutics. Moderate-to-Severe Atopic Dermatitis. Expected June 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9a29021e2a850bea6b4d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280101
SUMMARY:NRIX — NX-5948 (Phase 2)
DESCRIPTION:Nurix Therapeutics Inc.. Chronic Lymphocytic Leukemia (CLL)\; Small Lymphocytic Lymphoma (SLL). Expected January 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0e331755c71b9a82a1d7@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20291001
SUMMARY:NRIX — NX-5948 (Phase 3)
DESCRIPTION:Nurix Therapeutics Inc.. B-cell Lymphoma\; Chronic Lymphocytic Leukemia. Expected October 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c70988faa9909b34024b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20330501
SUMMARY:NRIX — NX-5948 (Phase 1/2)
DESCRIPTION:Nurix Therapeutics Inc.. B-cell Lymphoma\; Chronic Lymphocytic Leukemia. Expected May 2033 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:66451709c25caf3e9599@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:NUVL — Neladalkib (NVL-655) (Phase 1/2)
DESCRIPTION:Nuvalent Inc.. Locally Advanced Solid Tumor\; Metastatic Solid Tumor. Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:fa3b70b8ebdbe973bd8e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:NUVL — Zidesamtinib (NVL-520) (Phase 1/2)
DESCRIPTION:Nuvalent Inc.. Locally Advanced Solid Tumor\; Metastatic Solid Tumor. Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:70efe43b992e988a3e93@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20291201
SUMMARY:NUVL — Neladalkib (NVL-655) (Phase 3)
DESCRIPTION:Nuvalent Inc.. Non-small Cell Lung Cancer\; Anaplastic Lymphoma Kinase-positive. Expected December 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:85af306eef014d310255@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281001
SUMMARY:NVCR — NovoTTF-200T (Phase 3)
DESCRIPTION:NovoCure Limited. Metastatic Non-small Cell Lung Cancer. Expected October 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:cd8ef34f3337298aaa83@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290401
SUMMARY:NVCR — Optune® device (Phase 3)
DESCRIPTION:NovoCure Limited. Glioblastoma. Expected April 2029 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:fb56b6a87bfd76238587@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271001
SUMMARY:ORKA — ORKA-002 (Phase 2)
DESCRIPTION:Oruka Therapeutics Inc.. Plaque Psoriasis. Expected October 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:950402cbbc628c898eba@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281001
SUMMARY:ORKA — ORKA-002 (Phase 2)
DESCRIPTION:Oruka Therapeutics Inc.. Hidradenitis Suppurativa (HS). Expected October 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8f94898cd7b67ac1d55b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290701
SUMMARY:ORKA — ORKA-002 (Phase 2)
DESCRIPTION:Oruka Therapeutics Inc.. Plaque Psoriasis. Expected July 2029 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:cfc3e9b07a4f437280cf@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300501
SUMMARY:ORKA — ORKA-001 (Phase 2)
DESCRIPTION:Oruka Therapeutics Inc.. Plaque Psoriasis. Expected May 2030 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b036341feee73eb793fa@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:PCVX — 0.5 mL of the low dose VAX-31 (Phase 2)
DESCRIPTION:Vaxcyte Inc.. Pneumococcal Vaccines. Expected December 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:342c53c2a7c3d2fa8fab@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:PHVS — Deucrictibant (Phase 3)
DESCRIPTION:Pharvaris N.V.. Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH). Expected June 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ded61e0250306bdf1f15@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:PHVS — deucrictibant (Phase 2/3)
DESCRIPTION:Pharvaris N.V.. Hereditary Angioedema\; Hereditary Angioedema Type I. Expected June 2027 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b6dcd8e3b036b4ff7aea@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281201
SUMMARY:PHVS — Deucrictibant (Phase 3)
DESCRIPTION:Pharvaris N.V.. Hereditary Angioedema (HAE). Expected December 2028 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e987f3d85d4081de8fcb@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:PRAX — 1mg elsunersen (Phase 3)
DESCRIPTION:Praxis Precision Medicines Inc.. Epileptic Encephalopathy\; SCN2A Encephalopathy. Expected December 2026 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8689a16a5dbf6f9f8fb0@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:PRAX — 1.0mg/kg/day PRAX-562 (Phase 3)
DESCRIPTION:Praxis Precision Medicines Inc.. Developmental and Epileptic Encephalopathy 1. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:14825ae861e86d5da5f3@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:PRAX — 40 mg/day vormatrogine for 12 weeks (Phase 3)
DESCRIPTION:Praxis Precision Medicines Inc.. Focal Epilepsy. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:66740ffd38af721d3692@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280501
SUMMARY:PRAX — vormatrogine (Phase 3)
DESCRIPTION:Praxis Precision Medicines Inc.. Epilepsy\, Tonic-Clonic\; Focal Seizure. Expected May 2028 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4532e12206e31ea20888@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270901
SUMMARY:PTCT — PTC844 (Phase 2)
DESCRIPTION:PTC Therapeutics Inc.. Rheumatoid Arthritis. Expected September 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c112cf06b8c243decdfd@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:PTCT — Vatiquinone (Phase 3)
DESCRIPTION:PTC Therapeutics Inc.. Friedreich Ataxia. Expected December 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e771013a0d48c1eccaf0@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290301
SUMMARY:PTCT — Vatiquinone (Phase 3)
DESCRIPTION:PTC Therapeutics Inc.. Friedreich's Ataxia. Expected March 2029 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:90d7ca2808b61c9b1c12@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20310201
SUMMARY:PTCT — Sepiapterin (Phase 3)
DESCRIPTION:PTC Therapeutics Inc.. Phenylketonuria. Expected February 2031 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f9d781223a8a84e2f712@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:RARE — setrusumab (Phase 3)
DESCRIPTION:Ultragenyx Pharmaceutical Inc.. Osteogenesis Imperfecta. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:20188d762b3bbd47b8cc@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:RARE — No Investigational Product (Phase 3)
DESCRIPTION:Ultragenyx Pharmaceutical Inc.. Mucopolysaccharidosis IIIA\; MPS IIIA. Expected August 2027 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:373fc429bb3970afa3f5@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:RARE — Triheptanoin (Phase 3)
DESCRIPTION:Ultragenyx Pharmaceutical Inc.. Long-chain Fatty Acid Oxidation Disorders (LC-FAOD). Expected August 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:761025adc475279db401@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270901
SUMMARY:RARE — DTX301 (Phase 3)
DESCRIPTION:Ultragenyx Pharmaceutical Inc.. OTC Deficiency. Expected September 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6a13b365cc741e784c52@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281201
SUMMARY:RARE — UX016 (Phase 1/2)
DESCRIPTION:Ultragenyx Pharmaceutical Inc.. GNE Myopathy. Expected December 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ae46f488af7cf09e131d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290301
SUMMARY:RARE — UX111 (Phase 2/3)
DESCRIPTION:Ultragenyx Pharmaceutical Inc.. MPS IIIA\; Sanfilippo Syndrome. Expected March 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:fad970f7042168dcee46@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290301
SUMMARY:RARE — UX701 (Phase 1/2)
DESCRIPTION:Ultragenyx Pharmaceutical Inc.. Wilson Disease. Expected March 2029 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3deabea2ecf1d031007c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280401
SUMMARY:RCUS — Casdatifan (Phase 3)
DESCRIPTION:Arcus Biosciences Inc.. Metastatic Clear Cell Renal Cell Carcinoma\; Advanced Clear Cell Renal Cell Carcinoma. Expected April 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9ac3070729f88d7a723e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20301101
SUMMARY:RCUS — Quemliclustat (Phase 3)
DESCRIPTION:Arcus Biosciences Inc.. Metastatic Pancreatic Ductal Adenocarcinoma. Expected November 2030 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0f92eb43b6e527b430b5@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280401
SUMMARY:RLAY — Zovegalisib (Phase 3)
DESCRIPTION:Relay Therapeutics Inc.. PIK3CA Mutation\; HER2- Negative Breast Cancer. Expected April 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:dd3af525e44815bfd65e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290501
SUMMARY:RLAY — RLY-8161 (Phase 1/2)
DESCRIPTION:Relay Therapeutics Inc.. Advanced NRAS-Mutant Melanoma\; Advanced NRAS-Mutant Solid Tumors. Expected May 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6f963a8339a347189f4c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20310701
SUMMARY:RLAY — RLY-2608 (Phase 2)
DESCRIPTION:Relay Therapeutics Inc.. PIK3CA-Related Overgrowth Spectrum (PROS)\; Lymphatic Malformations. Expected July 2031 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8bad2b16ead0b4782f92@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:RYTM — Setmelanotide (Phase 3)
DESCRIPTION:Rhythm Pharmaceuticals Inc.. Hypothalamic Obesity\; Multiple Pituitary Hormone Deficiency Genetic Form. Expected March 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:aeada86640f4cdc9bb5d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:RYTM — Part A: RM-718 or placebo (matched to specific RM-718 dose c (Phase 1/2)
DESCRIPTION:Rhythm Pharmaceuticals Inc.. Hypothalamic Obesity\; Prader-Willi Syndrome. Expected May 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0207ba895ac9e53d3726@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280401
SUMMARY:RYTM — Bivamelagon (Phase 2)
DESCRIPTION:Rhythm Pharmaceuticals Inc.. Hypothalamic Obesity. Expected April 2028 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6314c5fcaa8b67016a4e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:SLS — SLS009 (Phase 1/2)
DESCRIPTION:SELLAS Life Sciences Group Inc.. Hematologic Malignancies. Expected December 2026 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f63022fcc2345d2f6ddd@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:SUPN — BIS-001ER (Phase 1/2)
DESCRIPTION:Supernus Pharmaceuticals Inc.. Focal Impaired Awareness Seizures. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:30f53826e86140693c61@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:SUPN — SPN-821 2400 mg (Phase 2)
DESCRIPTION:Supernus Pharmaceuticals Inc.. Major Depressive Disorder (MDD). Expected December 2026 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:544ca74c3a08d6798408@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:SUPN — SPN-817 (Phase 2)
DESCRIPTION:Supernus Pharmaceuticals Inc.. Focal Onset Seizures. Expected August 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:cf6ae9c9f87a9481991f@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:SUPN — SPN-817 (Phase 2)
DESCRIPTION:Supernus Pharmaceuticals Inc.. Epilepsy\; Seizures\, Epileptic. Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:cf6ae9c9f87a9481991f@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:SUPN — SPN-817 (Phase 2)
DESCRIPTION:Supernus Pharmaceuticals Inc.. Focal Onset Seizures. Expected December 2027 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:49af72c628795ed647d0@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:SWTX — Nirogacestat oral tablet (Phase 2)
DESCRIPTION:SpringWorks Therapeutics Inc.. Desmoid Tumor\; Aggressive Fibromatosis. Expected May 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d8081ba36642a1fc7815@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:SYRE — SPY001 (Phase 2)
DESCRIPTION:Spyre Therapeutics Inc.. Ulcerative Colitis\; Inflammatory Bowel Diseases. Expected June 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:96914f960e4e1a67d8de@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271001
SUMMARY:SYRE — SPY072 (Phase 2)
DESCRIPTION:Spyre Therapeutics Inc.. Hidradenitis Suppurativa (HS). Expected October 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f9b787af6c6eadd49577@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290301
SUMMARY:SYRE — SPY001 (Phase 2)
DESCRIPTION:Spyre Therapeutics Inc.. Ulcerative Colitis\; Inflammatory Bowel Diseases. Expected March 2029 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:68e1abbdb9bd7d397508@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:TARS — lotilaner (Phase 2)
DESCRIPTION:Tarsus Pharmaceuticals Inc.. Ocular Rosacea. Expected December 2026 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b36dab4e0986e1239c5e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271001
SUMMARY:TARS — TP-05 (lotilaner) Low Dose (Phase 2)
DESCRIPTION:Tarsus Pharmaceuticals Inc.. Lyme Disease. Expected October 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ee82aeec6c0eb18eb277@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280701
SUMMARY:TARS — TP-06 (Phase 2)
DESCRIPTION:Tarsus Pharmaceuticals Inc.. Persistent Corneal Epithelial Defect. Expected July 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:81c8f19cf2285cac8f15@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20291101
SUMMARY:TERN — MK-4208 (Phase 1/2)
DESCRIPTION:Terns Pharmaceuticals Inc.. Leukemia\, Myelogenous\, Chronic\, BCR-ABL Positive\; Chronic Myeloid Leukemia\, Chronic Phase. Expected November 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:82414db7eccd53816bca@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:TGTX — Ublituximab (Phase 3)
DESCRIPTION:TG Therapeutics Inc.. Relapsing Multiple Sclerosis. Expected January 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3fde2e0777dfd2241113@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270701
SUMMARY:TGTX — Ublituximab (Phase 2)
DESCRIPTION:TG Therapeutics Inc.. Multiple Sclerosis. Expected July 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:44805e5cc414317b109b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280701
SUMMARY:TGTX — Ublituximab (Phase 2)
DESCRIPTION:TG Therapeutics Inc.. Myasthenia Gravis. Expected July 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:cc6980287807eb02ae5f@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281201
SUMMARY:TGTX — Ublituximab (Phase 2)
DESCRIPTION:TG Therapeutics Inc.. Schizophrenia. Expected December 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:51ff95601406fbba1ccb@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300101
SUMMARY:TGTX — Ublituximab (Phase 2/3)
DESCRIPTION:TG Therapeutics Inc.. Relapsing Multiple Sclerosis. Expected January 2030 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6bba01a60bf069573987@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20320501
SUMMARY:TGTX — Ublituximab (Phase 3)
DESCRIPTION:TG Therapeutics Inc.. Relapsing Multiple Sclerosis (RMS). Expected May 2032 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5da752087c3b45200a48@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:TLX — 68Ga-PSMA-11 (Phase 3)
DESCRIPTION:Telix Pharmaceuticals Limited. PCA\; Prostate Cancer. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:52ea13f923cdb435d4f2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:TLX — 177Lu-TLX250 (Phase 3)
DESCRIPTION:Telix Pharmaceuticals Limited. ccRCC\; Renal Cell Carcinoma (Kidney Cancer). Expected August 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d10e7c6c38b2f999cda9@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:TLX — 177Lu-TLX591 (Phase 3)
DESCRIPTION:Telix Pharmaceuticals Limited. Metastatic Castration-resistant Prostate Cancer. Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4cea1c120abb0c5293f1@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280401
SUMMARY:TLX — Floretyrosine F 18 ([18F]FET) (Phase 3)
DESCRIPTION:Telix Pharmaceuticals Limited. Brain Metastasis\; Radiation Necrosis. Expected April 2028 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:cbe55ef510fd9d573634@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280701
SUMMARY:TLX — TLX-101-Tx + Lomustine (Phase 3)
DESCRIPTION:Telix Pharmaceuticals Limited. Neoplastic Disease\; Glioblastoma. Expected July 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:adc2be6aec09539ff475@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281201
SUMMARY:TLX — 177Lu-TLX250 (Phase 2)
DESCRIPTION:Telix Pharmaceuticals Limited. ccRCC\; Renal Cell Carcinoma (Kidney Cancer). Expected December 2028 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:76b7af985cf6132f8008@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:TRVI — NAL ER (Phase 3)
DESCRIPTION:Trevi Therapeutics Inc.. Idiopathic Pulmonary Fibrosis. Expected August 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:88c146c2697a5f790960@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270901
SUMMARY:TRVI — NAL ER (Phase 2)
DESCRIPTION:Trevi Therapeutics Inc.. Refractory Chronic Cough. Expected September 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2551314242df4a5d6b7e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280601
SUMMARY:TRVI — NAL ER (Phase 3)
DESCRIPTION:Trevi Therapeutics Inc.. Idiopathic Pulmonary Fibrosis. Expected June 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:20c076f69ce27e5bfd41@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:TVTX — Sparsentan (Phase 2)
DESCRIPTION:Travere Therapeutics Inc.. Focal Segmental Glomerulosclerosis\; Minimal Change Disease. Expected March 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b5ef4eab9edde140d5db@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270701
SUMMARY:TVTX — Pegtibatinase (Phase 1/2)
DESCRIPTION:Travere Therapeutics Inc.. Homocystinuria. Expected July 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:87dd4fc47018ad22ad87@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:TVTX — Pegtibatinase (Phase 3)
DESCRIPTION:Travere Therapeutics Inc.. Homocystinuria. Expected August 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:099ec10a3b81efee809a@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300801
SUMMARY:TVTX — Pegtibatinase (Phase 3)
DESCRIPTION:Travere Therapeutics Inc.. Homocystinuria. Expected August 2030 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e3f208c498aee8047af6@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271101
SUMMARY:VERA — Atacicept (Phase 2)
DESCRIPTION:Vera Therapeutics Inc.. pMN\; IgAN. Expected November 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:428862f9d35f958ce1ad@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20310501
SUMMARY:VERA — Atacicept 150 mg (Phase 2)
DESCRIPTION:Vera Therapeutics Inc.. IgA Nephropathy (IgAN)\; Renal and Urinary Disorders. Expected May 2031 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6143c37aa15ff7a20c5b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270701
SUMMARY:VKTX — VK2735 (Phase 3)
DESCRIPTION:Viking Therapeutics Inc.. Weight Loss. Expected July 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6143c37aa15ff7a20c5b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270701
SUMMARY:VKTX — VK2735 (Phase 3)
DESCRIPTION:Viking Therapeutics Inc.. Weight Loss. Expected July 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c685411c424c581cb7f1@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280701
SUMMARY:VKTX — VK2735 (Phase 3)
DESCRIPTION:Viking Therapeutics Inc.. Weight Loss. Expected July 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:15fb58502caf1d79c595@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281001
SUMMARY:VKTX — VK2735 Oral (Phase 3)
DESCRIPTION:Viking Therapeutics Inc.. Weight Loss. Expected October 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8a21c636be0acd915ea3@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:XENE — Azetukalner (Phase 3)
DESCRIPTION:Xenon Pharmaceuticals Inc.. Major Depressive Disorder. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3580fc795102b38bfafe@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:XENE — XEN1101 (Phase 3)
DESCRIPTION:Xenon Pharmaceuticals Inc.. Primary Generalized Tonic-Clonic Seizures. Expected April 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:95d702e366e5d99fc571@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:XENE — Azetukalner (Phase 3)
DESCRIPTION:Xenon Pharmaceuticals Inc.. Major Depressive Disorder. Expected May 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9074d301a1b053912d2c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280101
SUMMARY:XENE — XEN1101 (Phase 3)
DESCRIPTION:Xenon Pharmaceuticals Inc.. Focal Onset Seizures. Expected January 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:fec48d8de45ea37e66c7@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280601
SUMMARY:XENE — Azetukalner (Phase 3)
DESCRIPTION:Xenon Pharmaceuticals Inc.. Bipolar Disorder\; Bipolar Depression. Expected June 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2b802f41654f05a0e028@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290601
SUMMARY:XENE — Azetukalner (Phase 3)
DESCRIPTION:Xenon Pharmaceuticals Inc.. Bipolar Depression\; Bipolar I Disorder. Expected June 2029 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d881c80e760c144cbcee@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20330401
SUMMARY:XENE — XEN1101 (Phase 3)
DESCRIPTION:Xenon Pharmaceuticals Inc.. Focal Epilepsy\; Tonic-Clonic Seizures. Expected April 2033 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:308582adb6785dbeb5de@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:ZLAB — ZL-1109 (VRDN-003) (Phase 3)
DESCRIPTION:Zai Lab Limited. Thyroid Eye Disease (TED). Expected March 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a83b48018b528776a093@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:ZLAB — ZL-1310 (Phase 1/2)
DESCRIPTION:Zai Lab Limited. Solid Tumors. Expected August 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d70c4b285592e2167eab@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280601
SUMMARY:ZLAB — ZL-1310 (Phase 3)
DESCRIPTION:Zai Lab Limited. Small-cell Lung Cancer. Expected June 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3ae8135f19ee863ccd37@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300601
SUMMARY:ZLAB — ZL-1310 in combination with Atezolizumab or Durvalumab (Phase 3)
DESCRIPTION:Zai Lab Limited. Extensive-Stage Small Cell Lung Cancer. Expected June 2030 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2d67f441a2d8f5950d8a@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:AMGN — ABP 234 (Phase 3)
DESCRIPTION:Amgen Inc.. Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC). Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4f72e769ce6608dea4c3@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:AMGN — AMG 732 (Phase 1/2)
DESCRIPTION:Amgen Inc.. Thyroid Eye Disease. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:fe54032142697d5d06db@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:AMGN — Maridebart Cafraglutide (Phase 3)
DESCRIPTION:Amgen Inc.. Obesity. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:153dbea7ffa05bde6b34@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:AMGN — Maridebart cafraglutide (Phase 3)
DESCRIPTION:Amgen Inc.. Type 2 Diabetes Mellitus (T2DM)\, Obesity\, Overweight. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f07d628f994f9281c096@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:AMGN — Inebilizumab (Phase 2)
DESCRIPTION:Amgen Inc.. Neuromyelitis Optica Spectrum Disorder. Expected April 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b39cd2fd91b07f7f992c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:AMGN — Ocrelizumab (US) (Phase 3)
DESCRIPTION:Amgen Inc.. Relapsing-remitting Multiple Sclerosis (RRMS). Expected April 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4afa8876865429453c9d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:AMGN — Maridebart cafraglutide (Phase 3)
DESCRIPTION:Amgen Inc.. Obesity Disease. Expected April 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0eef413df9bf52ed3ad3@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:GILD — Sacituzumab Govitecan-hziy (Phase 3)
DESCRIPTION:Gilead Sciences Inc.. Metastatic Breast Cancer. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:730cd8096a229475433f@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:GILD — Tilpisertib Fosmecarbil (Phase 2)
DESCRIPTION:Gilead Sciences Inc.. Ulcerative Colitis. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:65f75fba3dc96f3b43a4@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270201
SUMMARY:GILD — Sacituzumab Govitecan-hziy (Phase 3)
DESCRIPTION:Gilead Sciences Inc.. Triple Negative Breast Cancer\; PD-L1 Positive. Expected February 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d273f38ed4bbc6cb8e96@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:GILD — Oral Lenacapavir (Phase 2)
DESCRIPTION:Gilead Sciences Inc.. HIV-1-infection. Expected March 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c952e54cd9a117625072@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:GILD — Sacituzumab Govitecan-hziy (SG) (Phase 2)
DESCRIPTION:Gilead Sciences Inc.. Non-small Cell Lung Cancer. Expected March 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a5fa22cea8e5697ec5d2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:GILD — Domvanalimab (Phase 2)
DESCRIPTION:Gilead Sciences Inc.. Head and Neck Squamous Cell Carcinoma. Expected March 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:016c287cd659e5bf142f@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:GILD — Sacituzumab Govitecan-hziy (Phase 1/2)
DESCRIPTION:Gilead Sciences Inc.. Advanced Solid Tumor\; Metastatic Triple-Negative Breast Cancer. Expected May 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1564a74c988536593325@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:GILD — Sacituzumab govitecan-hziy (SG) (Phase 3)
DESCRIPTION:Gilead Sciences Inc.. Triple Negative Breast Cancer. Expected June 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5e3a520fc285fd077beb@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:VRTX — Suzetrigine (Phase 3)
DESCRIPTION:Vertex Pharmaceuticals Inc.. Diabetic Peripheral Neuropathic Pain. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4ee97c179a3bef8391d0@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270201
SUMMARY:VRTX — VX-670 (Phase 1/2)
DESCRIPTION:Vertex Pharmaceuticals Inc.. Myotonic Dystrophy Type 1 (DM1). Expected February 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:99ba9499a93092c15741@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:VRTX — VX-264 (Phase 1/2)
DESCRIPTION:Vertex Pharmaceuticals Inc.. Type 1 Diabetes. Expected March 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0ce893cfa39bb47cdf73@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:VRTX — VX-993 (Phase 2)
DESCRIPTION:Vertex Pharmaceuticals Inc.. Diabetic Peripheral Neuropathic Pain. Expected March 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:acdeddd45453928bbf69@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:VRTX — ELX/TEZ/IVA (Phase 3)
DESCRIPTION:Vertex Pharmaceuticals Inc.. Cystic Fibrosis. Expected April 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ed1d64f9fe79d041fdd2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:VRTX — Suzetrigine (Phase 3)
DESCRIPTION:Vertex Pharmaceuticals Inc.. Diabetic Peripheral Neuropathic Pain. Expected April 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:11e200eeb9e40d78e34e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:VRTX — Suzetrigine (Phase 3)
DESCRIPTION:Vertex Pharmaceuticals Inc.. Diabetic Peripheral Neuropathic Pain. Expected May 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4ab5ac60b01f8cd8a907@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:VRTX — CTX001 (Phase 3)
DESCRIPTION:Vertex Pharmaceuticals Inc.. Sickle Cell Disease\; Hydroxyurea Failure. Expected June 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:71ee42091174a36ecae5@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:REGN — REGN7999 (Phase 2)
DESCRIPTION:Regeneron Pharmaceuticals Inc.. Non-Transfusion Dependent Beta-Thalassemia (NTDT). Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:03c9ace64a7fe8476c47@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:REGN — Alirocumab (Phase 2)
DESCRIPTION:Regeneron Pharmaceuticals Inc.. Hypercholesterolemia. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:111e841acf11ba748bb9@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:REGN — Fianlimab (Phase 3)
DESCRIPTION:Regeneron Pharmaceuticals Inc.. Melanoma. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:31eb7f39e5bc5470b883@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270201
SUMMARY:REGN — REGN7508 (Phase 2)
DESCRIPTION:Regeneron Pharmaceuticals Inc.. Atrial Fibrillation (AF). Expected February 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:31eb7f39e5bc5470b883@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270201
SUMMARY:REGN — REGN7508 (Phase 3)
DESCRIPTION:Regeneron Pharmaceuticals Inc.. Venous Thromboembolism (VTE). Expected February 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a5fd3a2c0c6ff237e4c7@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:MRNA — mRNA-1018-H5 (Phase 3)
DESCRIPTION:Moderna Inc.. Influenza. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c036874fd355155deebb@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270201
SUMMARY:MRNA — mRNA-1403 (Phase 3)
DESCRIPTION:Moderna Inc.. Acute Gastroenteritis\; Norovirus Acute Gastroenteritis. Expected February 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6a8c4c265b818cf232a1@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:MRNA — mRNA-1647 (Phase 2)
DESCRIPTION:Moderna Inc.. Cytomegalovirus Infection. Expected March 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1f890b289e7a051985f0@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:MRNA — mRNA-3927 (Phase 1/2)
DESCRIPTION:Moderna Inc.. Propionic Acidemia. Expected August 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5454e088dce8b2f35cbc@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281101
SUMMARY:MRNA — mRNA-1982 (Phase 2)
DESCRIPTION:Moderna Inc.. Lyme Disease. Expected November 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e91d5d0c83a74cab65a6@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290101
SUMMARY:MRNA — mRNA-1195 (Phase 2)
DESCRIPTION:Moderna Inc.. Multiple Sclerosis. Expected January 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:34a87c723ff04efd5d65@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290801
SUMMARY:MRNA — mRNA-1283 (Phase 2)
DESCRIPTION:Moderna Inc.. SARS-CoV-2. Expected August 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1167ef051b17a0f1703d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:ARGX — Efgartigimod IV (Phase 2/3)
DESCRIPTION:argenx SE. Generalized Myasthenia Gravis. Expected March 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:71550d84777477f43c17@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:ARGX — Efgartigimod PH20 SC (Phase 2)
DESCRIPTION:argenx SE. Systemic Sclerosis (SSc). Expected March 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1ac7a2a475b2a3e2f079@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:ARGX — Efgartigimod PH20 SC (Phase 2)
DESCRIPTION:argenx SE. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Expected April 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b1a5cbf4b50d92b3eb8a@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270701
SUMMARY:ARGX — Efgartigimod PH20 SC (Phase 3)
DESCRIPTION:argenx SE. Primary Sjogrens Disease. Expected July 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6318fe17a01091336b77@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270901
SUMMARY:ARGX — Efgartigimod PH20 SC (Phase 2/3)
DESCRIPTION:argenx SE. Generalized Myasthenia Gravis. Expected September 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d5907c8529fa543c0fdb@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270901
SUMMARY:ARGX — empasiprubart (Phase 3)
DESCRIPTION:argenx SE. Chronic Inflammatory Demyelinating Polyneuropathy\; CIDP. Expected September 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:dc7b2f89531fc79d4ab2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271001
SUMMARY:ARGX — Empasiprubart IV (Phase 2)
DESCRIPTION:argenx SE. AChR-Ab Seropositive Generalized Myasthenia Gravis\; Myasthenia Gravis (MG). Expected October 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:cd9045f5f7ff9edac88b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:BIIB — Felzartamab (Phase 3)
DESCRIPTION:Biogen Inc.. Antibody-mediated Rejection. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2a7c7fe6d4e65627ebfe@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:BIIB — BIIB017 (peginterferon beta-1a) (Phase 3)
DESCRIPTION:Biogen Inc.. Multiple Sclerosis\, Relapsing-Remitting. Expected May 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:780e66ad3930d0520925@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:BIIB — Felzartamab (Phase 3)
DESCRIPTION:Biogen Inc.. Immunoglobulin A Nephropathy (IgAN). Expected May 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d3db1c5da4b664b28440@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:BIIB — Tofersen (Phase 3)
DESCRIPTION:Biogen Inc.. Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation. Expected August 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:789db9aa98619cb6087b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270901
SUMMARY:BIIB — Nusinersen (Phase 3)
DESCRIPTION:Biogen Inc.. Spinal Muscular Atrophy. Expected September 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b218aefb1dec711713f0@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271101
SUMMARY:BIIB — Omaveloxolone (Phase 3)
DESCRIPTION:Biogen Inc.. Friedreich Ataxia. Expected November 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:564b662e7f61a26ddce4@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280101
SUMMARY:BIIB — Felzartamab (Phase 2)
DESCRIPTION:Biogen Inc.. Graves' Disease. Expected January 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f3103c399041cc5f7d85@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280201
SUMMARY:BIIB — Felzartamab (Phase 2)
DESCRIPTION:Biogen Inc.. Microvascular Inflammation. Expected February 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:905e58ace5cdba4f276d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:ALNY — ALN-2232 (Phase 1/2)
DESCRIPTION:Alnylam Pharmaceuticals Inc.. Obesity. Expected April 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:266d236cd08625afa04b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270501
SUMMARY:ALNY — ALN-4324 (Phase 2)
DESCRIPTION:Alnylam Pharmaceuticals Inc.. Type 2 Diabetes Mellitus (T2DM). Expected May 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7de7f8fce6823e84dc15@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:ALNY — ALN-6400 (Phase 2)
DESCRIPTION:Alnylam Pharmaceuticals Inc.. Von Willebrand Disease (VWD)\; Heavy Menstrual Bleeding (HMB). Expected June 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f28065dff604ca1ac7a6@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:ALNY — ALN-APP (Phase 2)
DESCRIPTION:Alnylam Pharmaceuticals Inc.. Cerebral Amyloid Angiopathy. Expected August 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7af66f1b852f03d52c97@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:ALNY — ALN-4324 (Phase 1/2)
DESCRIPTION:Alnylam Pharmaceuticals Inc.. Obese or Overweight Healthy Volunteers\; Type 2 Diabetes Mellitus (T2DM). Expected August 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d5494199b1432fe45e52@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:ALNY — Nucresiran (Phase 3)
DESCRIPTION:Alnylam Pharmaceuticals Inc.. Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy\; hATTR-PN. Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:051b5899be8218522f17@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280101
SUMMARY:ALNY — ALN-6400 (Phase 1/2)
DESCRIPTION:Alnylam Pharmaceuticals Inc.. Hereditary Hemorrhagic Telangiectasia. Expected January 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7402342ac581bc2bcde7@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280301
SUMMARY:ALNY — Vutrisiran (Phase 3)
DESCRIPTION:Alnylam Pharmaceuticals Inc.. Transthyretin Amyloidosis (ATTR) With Cardiomyopathy. Expected March 2028 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:cceea0c1f798df8eaaf3@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:INSM — Treprostinil Palmitil (Phase 2/3)
DESCRIPTION:Insmed Incorporated. Pulmonary Arterial Hypertension. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d8cf5af4fbb74e31afe2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281201
SUMMARY:INSM — Treprostinil Palmitil Inhalation Powder (Phase 3)
DESCRIPTION:Insmed Incorporated. Pulmonary Arterial Hypertension. Expected December 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d8cf5af4fbb74e31afe2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281201
SUMMARY:INSM — Treprostinil Palmitil Inhalation Powder (Phase 3)
DESCRIPTION:Insmed Incorporated. Pulmonary Hypertension\; Interstitial Lung Disease. Expected December 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d6a2c93b5cc31eb204b2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300801
SUMMARY:INSM — Treprostinil Palmitil Inhalation Powder (Phase 3)
DESCRIPTION:Insmed Incorporated. Progressive Pulmonary Fibrosis\; Interstitial Lung Disease. Expected August 2030 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e3916532fb1510135691@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20310101
SUMMARY:INSM — Treprostinil Palmitil Inhalation Powder (Phase 3)
DESCRIPTION:Insmed Incorporated. Pulmonary Hypertension\; Interstitial Lung Disease. Expected January 2031 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:97a222cdf150e40ae5c5@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:BNTX — BNT162b2 (Phase 3)
DESCRIPTION:BioNTech SE. COVID-19 Vaccines. Expected April 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d238c485015893ebe78e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:BNTX — BNT327 Dose Level 1 (DL1) (Phase 2)
DESCRIPTION:BioNTech SE. Extensive-stage Small-cell Lung Cancer\; Small-cell Lung Cancer. Expected June 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b8018a052690df9083cb@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270601
SUMMARY:BNTX — BNT166a (Phase 2)
DESCRIPTION:BioNTech SE. Mpox (Monkeypox)\; Smallpox. Expected June 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:535de603f9647fe733b0@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271101
SUMMARY:BNTX — BNT3212 (Phase 1/2)
DESCRIPTION:BioNTech SE. Advanced Solid Tumor. Expected November 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:09e2ef2452102ca9f477@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:BNTX — Pumitamig (Phase 2)
DESCRIPTION:BioNTech SE. Pancreatic Ductal Adenocarcinoma (PDAC). Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:2948c90d9dd9d3f8bfec@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280101
SUMMARY:BNTX — Pumitamig (Phase 2)
DESCRIPTION:BioNTech SE. Recurrent Glioblastoma. Expected January 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:7f5398b392a2a158f4af@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280301
SUMMARY:BNTX — BNT326 (Phase 1/2)
DESCRIPTION:BioNTech SE. Advanced Solid Tumor. Expected March 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:df232a80440fc833f74a@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:INCY — Povorcitinib (Phase 3)
DESCRIPTION:Incyte Corporation. Hidradenitis Suppurativa (HS). Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5ca24be6f79cd49c9c1a@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270101
SUMMARY:INCY — INCA034176 (Phase 1/2)
DESCRIPTION:Incyte Corporation. Chronic Graft-versus-host-disease. Expected January 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6d1b9b9bd8e79d8f8e07@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:INCY — INCB123667 (Phase 2)
DESCRIPTION:Incyte Corporation. Ovarian Cancer. Expected April 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ae132efce2b5b4c11c3d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:INCY — Ruxolitinib Cream (Phase 3)
DESCRIPTION:Incyte Corporation. NonSegmental Vitiligo. Expected April 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:eebb3fdb5efef5a73f48@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270701
SUMMARY:INCY — INCB000928 (Phase 2)
DESCRIPTION:Incyte Corporation. Fibrodysplasia Ossificans Progressiva (FOP). Expected July 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d08fc3eb73317639d9d7@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:INCY — Tafasitamab (Phase 2)
DESCRIPTION:Incyte Corporation. Hematologic Malignancies. Expected August 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:647d78aa8014fcb5eedd@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:UTHR — Ralinepag (Phase 3)
DESCRIPTION:United Therapeutics Corporation. PAH\; Pulmonary Hypertension. Expected December 2026 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:ce5fbdfe389e36370b08@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271101
SUMMARY:UTHR — Inhaled Treprostinil (Phase 3)
DESCRIPTION:United Therapeutics Corporation. Progressive Pulmonary Fibrosis\; Interstitial Lung Disease. Expected November 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:1af409d8309d0c470029@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280501
SUMMARY:UTHR — treprostinil SMI (treprostinil inhalation spray) (Phase 2)
DESCRIPTION:United Therapeutics Corporation. Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease. Expected May 2028 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a20aa87afcc80f13fc28@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281001
SUMMARY:UTHR — 10 GE Xenokidney (Phase 1/2)
DESCRIPTION:United Therapeutics Corporation. ESRD (End-Stage Renal Disease)\; Kidney Transplantation. Expected October 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a20e4119b7bc426e56bc@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20291101
SUMMARY:UTHR — GGTA1 KO Thymokidney (Phase 1/2)
DESCRIPTION:United Therapeutics Corporation. ESRD (End-Stage Renal Disease)\; Kidney Transplantation. Expected November 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:6022831ae2d857a488cb@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20291201
SUMMARY:UTHR — Inhaled Treprostinil (Phase 3)
DESCRIPTION:United Therapeutics Corporation. Idiopathic Pulmonary Fibrosis\; Interstitial Lung Disease. Expected December 2029 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:32deaf37b46029ef86f8@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20340901
SUMMARY:UTHR — treprostinil SMI (treprostinil inhalation spray) (Phase 2/3)
DESCRIPTION:United Therapeutics Corporation. Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease. Expected September 2034 (Not Yet Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e2ff83a99fc1a8673b89@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:JAZZ — Zanidatamab (Phase 2)
DESCRIPTION:Jazz Pharmaceuticals plc. Breast Cancer\; Gastric Cancer. Expected December 2026 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:3a18b4d01f0a2dca6612@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:JAZZ — Xywav (Phase 3)
DESCRIPTION:Jazz Pharmaceuticals plc. Narcolepsy\; Idiopathic Hypersomnia. Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e49264a2fe414cc1974c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:JAZZ — Zanidatamab (Phase 2)
DESCRIPTION:Jazz Pharmaceuticals plc. HER2-positive Breast Cancer\; Breast Cancer. Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4c1ddc98a46f1a61e525@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280101
SUMMARY:JAZZ — Lurbinectedin (Phase 1/2)
DESCRIPTION:Jazz Pharmaceuticals plc. Refractory Ewing Sarcoma\; Relapsed Ewing Sarcoma. Expected January 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:e44de2f71e434608c7bd@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280401
SUMMARY:JAZZ — Zanidatamab (Phase 3)
DESCRIPTION:Jazz Pharmaceuticals plc. Metastatic HER2-positive Breast Cancer. Expected April 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:48682432b0d6961ac19c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280601
SUMMARY:JAZZ — Dordaviprone (ONC201) (Phase 3)
DESCRIPTION:Jazz Pharmaceuticals plc. H3 K27M\; Glioma. Expected June 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8e329ac969ae0feba10d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280801
SUMMARY:JAZZ — JZP926 capsule (Phase 2/3)
DESCRIPTION:Jazz Pharmaceuticals plc. Juvenile Myoclonic Epilepsy. Expected August 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:d4d0591183fc3e5581ad@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281001
SUMMARY:JAZZ — JZP3507 (Phase 2)
DESCRIPTION:Jazz Pharmaceuticals plc. Meningioma. Expected October 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:990c4802b6e15e4e1dea@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270201
SUMMARY:NBIX — NBI-1065890 (Phase 2)
DESCRIPTION:Neurocrine Biosciences Inc.. Tardive Dyskinesia. Expected February 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f95d19f569aed77d885d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270701
SUMMARY:NBIX — NBI-1065845 (Phase 3)
DESCRIPTION:Neurocrine Biosciences Inc.. Major Depressive Disorder. Expected July 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f95d19f569aed77d885d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270701
SUMMARY:NBIX — NBI-1065845 (Phase 3)
DESCRIPTION:Neurocrine Biosciences Inc.. Major Depressive Disorder. Expected July 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f95d19f569aed77d885d@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270701
SUMMARY:NBIX — NBI-1065845 (Phase 3)
DESCRIPTION:Neurocrine Biosciences Inc.. Major Depressive Disorder. Expected July 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9514d6b113371cee6943@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270801
SUMMARY:NBIX — NBI-1117570 (Phase 2)
DESCRIPTION:Neurocrine Biosciences Inc.. Schizophrenia. Expected August 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:aec1be6ae73c2a89352f@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271001
SUMMARY:NBIX — NBI-1117568 (Phase 3)
DESCRIPTION:Neurocrine Biosciences Inc.. Schizophrenia. Expected October 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:959d85ae47bf8fc1c9a5@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271101
SUMMARY:NBIX — NBI-1117568 (Phase 3)
DESCRIPTION:Neurocrine Biosciences Inc.. Schizophrenia. Expected November 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5df5082763b23e1cda4b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280201
SUMMARY:NBIX — NBI-1117568 (Phase 2)
DESCRIPTION:Neurocrine Biosciences Inc.. Bipolar I Disorder\; Mania. Expected February 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a1e13187afb1f502f0b7@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:EXEL — XL092 (Phase 3)
DESCRIPTION:Exelixis Inc.. Non-Clear Cell Renal Cell Carcinoma. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:bada06e60d56650b6134@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280201
SUMMARY:EXEL — Zanzalintinib (Phase 2)
DESCRIPTION:Exelixis Inc.. Meningioma. Expected February 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:a24444221392db4657cd@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280601
SUMMARY:EXEL — Carboplatin (Phase 2)
DESCRIPTION:Exelixis Inc.. Squamous Non-Small Cell Lung Cancer (NSCLC). Expected June 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:4403afcfaf8a0be5b65a@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280801
SUMMARY:EXEL — Zanzalintinib (Phase 2/3)
DESCRIPTION:Exelixis Inc.. Head and Neck Squamous Cell Carcinoma. Expected August 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:98e9d8042bee7068305e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290601
SUMMARY:EXEL — Zanzalintinib (Phase 2/3)
DESCRIPTION:Exelixis Inc.. Pancreatic Neuroendocrine Tumor (pNET)\; Extra-Pancreatic Neuroendocrine Tumor (epNET). Expected June 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:99a3b8cb2eadba282d21@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300401
SUMMARY:EXEL — Zanzalintinib (Phase 3)
DESCRIPTION:Exelixis Inc.. Colorectal Cancer. Expected April 2030 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:df089c74f957bd96c69c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20300501
SUMMARY:EXEL — Cabozantinib (Phase 3)
DESCRIPTION:Exelixis Inc.. Cancer\; Renal Cell Carcinoma (RCC). Expected May 2030 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:8d6592f04cca3585e8e7@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270401
SUMMARY:BMRN — BMN 351 (Phase 1/2)
DESCRIPTION:BioMarin Pharmaceutical Inc.. Duchenne Muscular Dystrophy. Expected April 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f67b168badc6592ce067@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:BMRN — BMN 307 (Phase 1/2)
DESCRIPTION:BioMarin Pharmaceutical Inc.. Phenylketonuria (PKU). Expected December 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b02d8d1551b01d6e1a88@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:BMRN — BMN 111 (Phase 2)
DESCRIPTION:BioMarin Pharmaceutical Inc.. Achondroplasia. Expected December 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:5089cc07de5b44711410@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:BMRN — vosoritide (Phase 2)
DESCRIPTION:BioMarin Pharmaceutical Inc.. Achondroplasia. Expected December 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0f615e337210f565875c@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280601
SUMMARY:BMRN — Vosoritide (Phase 2)
DESCRIPTION:BioMarin Pharmaceutical Inc.. Hypochondroplasia. Expected June 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:779d2d0961b1124e8790@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20281101
SUMMARY:BMRN — Dose 1 of BMN 331 (Phase 1/2)
DESCRIPTION:BioMarin Pharmaceutical Inc.. Hereditary Angioedema\; HAE. Expected November 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b402b4a01c18dfeef115@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290601
SUMMARY:BMRN — BMN 333 (Phase 2/3)
DESCRIPTION:BioMarin Pharmaceutical Inc.. Achondroplasia. Expected June 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:0bb4a1a86a8291c149eb@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20310601
SUMMARY:BMRN — BMN 111 (Phase 3)
DESCRIPTION:BioMarin Pharmaceutical Inc.. Achondroplasia. Expected June 2031 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:080deafcb25f9be9b1cf@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:MDGL — Resmetirom (Phase 3)
DESCRIPTION:Madrigal Pharmaceuticals Inc.. NASH\; Cirrhosis\, Liver. Expected December 2026 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:b9aa08e08da60e582b92@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20270301
SUMMARY:MDGL — Resmetirom (Phase 3)
DESCRIPTION:Madrigal Pharmaceuticals Inc.. Non-Alcoholic Fatty Liver Disease. Expected March 2027 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:f6f56250975b8a2f7e2e@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280101
SUMMARY:MDGL — MGL-3196 (Phase 3)
DESCRIPTION:Madrigal Pharmaceuticals Inc.. NASH - Nonalcoholic Steatohepatitis. Expected January 2028 (Ongoing). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:924922dbd83174c61ca2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280801
SUMMARY:MDGL — Resmetirom (Phase 2)
DESCRIPTION:Madrigal Pharmaceuticals Inc.. MASH - Metabolic Dysfunction-Associated Steatohepatitis. Expected August 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:9842886f2507b2a60d60@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20290701
SUMMARY:MDGL — Resmetirom (Phase 2)
DESCRIPTION:Madrigal Pharmaceuticals Inc.. MASH\; MASH - Metabolic Dysfunction-Associated Steatohepatitis. Expected July 2029 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:277146ce0a750e38d8f2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:AXSM — Solriamfetol 150 mg (Phase 3)
DESCRIPTION:Axsome Therapeutics Inc.. Excessive Sleepiness\; Shift-work Disorder. Expected December 2026 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:277146ce0a750e38d8f2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20261201
SUMMARY:AXSM — Solriamfetol 150 mg (Phase 3)
DESCRIPTION:Axsome Therapeutics Inc.. Binge-Eating Disorder. Expected December 2026 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:fc68c4e2d97e4c401c62@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:AXSM — AXS-05 (dextromethorphan-bupropion) (Phase 3)
DESCRIPTION:Axsome Therapeutics Inc.. Smoking Cessation. Expected December 2027 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:52cf8f56d8051d4fe7a2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:AXSM — Solriamfetol (Phase 3)
DESCRIPTION:Axsome Therapeutics Inc.. Binge-Eating Disorder. Expected December 2027 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:52cf8f56d8051d4fe7a2@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20271201
SUMMARY:AXSM — Solriamfetol (Phase 3)
DESCRIPTION:Axsome Therapeutics Inc.. ADHD. Expected December 2027 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:744c9bbb1b3b8ae28cb4@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280301
SUMMARY:AXSM — AXS-14 (Esreboxetine) (Phase 3)
DESCRIPTION:Axsome Therapeutics Inc.. Fibromyalgia. Expected March 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:87f9857429ea2793409b@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280501
SUMMARY:AXSM — AXS-14 (esreboxetine) (Phase 3)
DESCRIPTION:Axsome Therapeutics Inc.. Fibromyalgia. Expected May 2028 (Enrolling). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:c751991ebacfefc98d9a@biotechivmonitor.com
DTSTAMP:20261117T203532Z
DTSTART;VALUE=DATE:20280601
SUMMARY:AXSM — Solriamfetol Dose A (Phase 3)
DESCRIPTION:Axsome Therapeutics Inc.. ADHD. Expected June 2028 (Recruiting). Company-guided primary completion date\, not a results-release date.
URL:https://biotechivmonitor.com/calendar
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
